NCT03001310View on ClinicalTrials.gov

Gene Therapy for Achromatopsia (CNGB3)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 16, 2017

Primary Completion Date

October 25, 2019

Study Completion Date

October 25, 2019

Conditions
Achromatopsia
Interventions
BIOLOGICAL

AAV - CNGB3

Comparison of different dosages of AAV-CNGB3

Trial Locations (2)

MI 48105

University of Michigan Kellog Eye Centre, Ann Arbor

Unknown

Moorfields Eye Hospital NHS Foundation Trust, London

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

MeiraGTx UK II Ltd

INDUSTRY

NCT03001310 - Gene Therapy for Achromatopsia (CNGB3) | Biotech Hunter | Biotech Hunter